Kinetics of Activated Thrombin-activatable Fibrinolysis Inhibitor (TAFIa)-catalyzed Cleavage of C-terminal Lysine Residues of Fibrin Degradation Products and Removal of Plasminogen-binding Sites

作者: Jonathan H. Foley , Paul F. Cook , Michael E. Nesheim

DOI: 10.1074/JBC.M110.215061

关键词:

摘要: Partial digestion of fibrin by plasmin exposes C-terminal lysine residues, which comprise new binding sites for both plasminogen and tissue-type plasminogen activator (tPA). This binding increases the catalytic efficiency of plasminogen activation by 3000-fold compared with tPA alone. The activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrinolysis by removing these residues, which causes a 97% reduction in tPA catalytic efficiency. The aim of this study was to determine the kinetics of TAFIa-catalyzed lysine cleavage from fibrin degradation products and the kinetics of loss of plasminogen-binding sites. We show that the kcat and Km of Glu1-plasminogen (Glu-Pg)-binding site removal are 2.34 s−1 and 142.6 nm, respectively, implying a catalytic efficiency of 16.21 μm−1 s−1. The corresponding values of Lys77/Lys78-plasminogen (Lys-Pg)-binding site removal are 0.89 s−1 and 96 nm implying a catalytic efficiency of 9.23 μm−1 s−1. These catalytic efficiencies of plasminogen-binding site removal by TAFIa are the highest of any TAFIa-catalyzed reaction with a biological substrate reported to date and suggest that plasmin-modified fibrin is a primary physiological substrate for TAFIa. We also show that the catalytic efficiency of cleavage of all C-terminal lysine residues, whether they are involved in plasminogen binding or not, is 1.10 μm−1 s−1. Interestingly, this value increases to 3.85 μm−1 s−1 in the presence of Glu-Pg. These changes are due to a decrease in Km. This suggests that an interaction between TAFIa and plasminogen comprises a component of the reaction mechanism, the plausibility of which was established by showing that TAFIa binds both Glu-Pg and Lys-Pg.

参考文章(25)
Jeffries Wyman, LINKED FUNCTIONS AND RECIPROCAL EFFECTS IN HEMOGLOBIN: A SECOND LOOK. Advances in Protein Chemistry. ,vol. 19, pp. 223- 286 ,(1964) , 10.1016/S0065-3233(08)60190-4
D. Collen, H.R. Lijnen, Matrix metalloproteinase system deficiencies and matrix degradation. Thrombosis and Haemostasis. ,vol. 82, pp. 837- 845 ,(1999) , 10.1055/S-0037-1615920
Désiré Collen, The Plasminogen (Fibrinolytic) System Thrombosis and Haemostasis. ,vol. 82, pp. 259- 270 ,(1999) , 10.1055/S-0037-1615841
Anthony K. Tan, Dan L. Eaton, Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry. ,vol. 34, pp. 5811- 5816 ,(1995) , 10.1021/BI00017A012
Laszlo Bajzar, Reg Manuel, Michael E. Nesheim, Purification and Characterization of TAFI, a Thrombin-activable Fibrinolysis Inhibitor Journal of Biological Chemistry. ,vol. 270, pp. 14477- 14484 ,(1995) , 10.1074/JBC.270.24.14477
Timothy Myles, Toshihiko Nishimura, Thomas H. Yun, Mariko Nagashima, John Morser, Andrew J. Patterson, Ronald G. Pearl, Lawrence L. K. Leung, Thrombin Activatable Fibrinolysis Inhibitor, a Potential Regulator of Vascular Inflammation * Journal of Biological Chemistry. ,vol. 278, pp. 51059- 51067 ,(2003) , 10.1074/JBC.M306977200
J. Morser, E.C. Gabazza, T. Myles, L.L.K. Leung, What has been learnt from the thrombin‐activatable fibrinolysis inhibitor‐deficient mouse? Journal of Thrombosis and Haemostasis. ,vol. 8, pp. 868- 876 ,(2010) , 10.1111/J.1538-7836.2010.03787.X
Zongchao Jia, TAFI: structured for self-destruction. Blood. ,vol. 112, pp. 2597- 2598 ,(2008) , 10.1182/BLOOD-2008-07-167734
Zuzana Valnickova, Ida B. Thøgersen, Jan Potempa, Jan J. Enghild, Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase. Journal of Biological Chemistry. ,vol. 282, pp. 3066- 3076 ,(2007) , 10.1074/JBC.M606559200
Paula Y.G. Kim, Jonathan Foley, Grace Hsu, Paul Y. Kim, Michael E. Nesheim, An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma. Analytical Biochemistry. ,vol. 372, pp. 32- 40 ,(2008) , 10.1016/J.AB.2007.09.034